Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
259.41
-2.68 (-1.02%)
Aug 14, 2026, 10:46 AM EDT - Market open
Johnson & Johnson Market Cap
Johnson & Johnson has a market cap or net worth of $625.14 billion as of August 14, 2026. Its market cap has increased by 48.82% in one year.
Market Cap
625.14B
Enterprise Value
653.42B
1-Year Change
48.82%
Ranking
Category
Stock Price
$259.41
ChartMarket Cap Chart
Since December 1, 1998, Johnson & Johnson's market cap has increased from $108.92B to $625.14B, an increase of 473.95%. That is a compound annual growth rate of 6.51%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 14, 2026 | 625.14B | 25.38% |
| Dec 31, 2025 | 498.60B | 43.20% |
| Dec 31, 2024 | 348.19B | -7.72% |
| Dec 29, 2023 | 377.32B | -18.30% |
| Dec 30, 2022 | 461.85B | 2.55% |
| Dec 31, 2021 | 450.36B | 8.70% |
| Dec 31, 2020 | 414.31B | 7.92% |
| Dec 31, 2019 | 383.91B | 10.92% |
| Dec 31, 2018 | 346.11B | -7.79% |
| Dec 29, 2017 | 375.36B | 19.76% |
| Dec 30, 2016 | 313.43B | 10.28% |
| Dec 31, 2015 | 284.22B | -2.90% |
| Dec 31, 2014 | 292.70B | 13.27% |
| Dec 31, 2013 | 258.42B | 33.02% |
| Dec 31, 2012 | 194.27B | 8.47% |
| Dec 30, 2011 | 179.09B | 5.44% |
| Dec 31, 2010 | 169.86B | -4.42% |
| Dec 31, 2009 | 177.71B | 7.05% |
| Dec 31, 2008 | 166.00B | -13.03% |
| Dec 31, 2007 | 190.88B | -0.28% |
| Dec 29, 2006 | 191.42B | 7.06% |
| Dec 30, 2005 | 178.79B | -5.00% |
| Dec 31, 2004 | 188.21B | 22.75% |
| Dec 31, 2003 | 153.33B | -3.90% |
| Dec 31, 2002 | 159.55B | -11.43% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 1.09T |
| AbbVie | 440.98B |
| Merck & Co. | 328.06B |
| Novartis AG | 294.87B |
| AstraZeneca | 248.17B |
| Amgen | 225.57B |
| Novo Nordisk | 209.73B |
| Gilead Sciences | 169.75B |